Advances in Neuropharmacological Therapies: From Molecular Discoveries to Personalized Clinical Applications

As part of the 10th Mediterranean Neuroscience Society Conference, we are excited to present this new collection of articles exploring recent advances in Neuropharmacological Therapies.

Neuropharmacology bridges fundamental neuroscience and clinical therapeutics, transforming molecular and cellular insights into effective clinical treatments for neurological disorders. Despite advances made possible by innovative technologies (including molecular genetics, precision genomic editing, computational biology, and personalized medicine), many challenges remain. Addressing barriers, such as targeted drug specificity, resistance, effective blood-brain barrier penetration, ethical concerns, and regulatory considerations, is critical to future breakthroughs in treating neurodegenerative disorders, psychiatric illnesses, and other complex neurological conditions.

Recent years have witnessed tremendous scientific advances enabling greater understanding of neuronal circuitry, molecular pathways, and the genetic underpinnings of neurological disorders. Technologies like CRISPR-Cas9, optogenetics, high-throughput drug discovery, and precision personalized medicine approaches have significantly accelerated therapeutic possibilities. While promising, translating these molecular findings into clinical solutions necessitates overcoming key barriers, including improved specificity of drug actions, drug delivery dynamics, and effective individualized interventions.

This Research Topic seeks submissions bridging basic science discoveries with clinical interventions, aiming to accelerate progress toward personalized neuropharmacological therapies. It includes original research, reviews, perspectives, and clinical-translational studies emphasizing innovative therapies for neurological and psychiatric disorders, covering, but not limited to, the following topics:

- Exploration of novel pharmacological targets within molecular and genetic pathways linked to neurological diseases, using technologies like CRISPR-Cas9, RNA editing, and genomic profiling to identify and modify druggable sites.

- Evaluation of novel preclinical neuropharmacological models assessing drug efficacy, safety profiles, and translational potential, providing insight into pharmacokinetics, pharmacodynamics, and mechanistic approaches.

- Analysis of clinical trials and case studies that successfully translate advances in molecular neuropharmacology into practical drug interventions, highlighting pharmacological efficacy, therapeutic outcomes, and safety in human subjects.

- Development of frameworks for personalized neuropharmacological treatments, focusing on biomarker-driven drug development, pharmacogenomics, and individualized therapeutic strategies tailored to genetic profiles.

- Advancements in neuropharmacology: concentrating on integrating genetic and biotechnological methods in drug development and their implications for clinical practice.

Article types and fees

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Case Report
• Clinical Trial
• Community Case Study
• Data Report
• Editorial
• FAIR² Data
• General Commentary
• Hypothesis and Theory
• ... View all formats

Articles that are accepted for publication by our external editors following rigorous peer review incur a publishing fee charged to Authors, institutions, or funders.

Article types

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Case Report
• Clinical Trial
• Community Case Study
• Data Report
• Editorial
• FAIR² Data
• General Commentary
• Hypothesis and Theory
• Methods
• Mini Review
• Opinion
• Original Research
• Perspective
• Review
• Study Protocol
• Systematic Review
• Technology and Code

Keywords: Neuropharmacological Therapies, Personalized Clinical Applications, novel pharmacological targets, druggable sites, biomarker-driven drug development, clinical practice.

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.